Ask AI
ProCE Banner Activity

FAQs: Expert Perspectives on Treatment Decision-making for Patients with CLL/SLL Based on the Latest Evidence

Clinical Thought

In this commentary expert faculty address questions regarding optimal approaches for the selection of treatment for patients with CLL/SLL, including treatments for patients who have developed resistance to a covalent BTK inhibitor and those with disease refractory to both a covalent BTK inhibitor and a BCL-2 inhibitor.

Released: July 16, 2025

Expiration: January 15, 2026

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca and Lilly. This activity is supported by an independent medical education grant from AbbVie.

AbbVie

AstraZeneca

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner

Disclosure

Primary Author

Brad Kahl, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Incyte, Lilly, Merck, Pfizer, Roche.